Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and dry mouth. Topiramate also carries a risk of birth defects, so it should ...

A growing number of options—from manufacturer discounts to trusted online pharmacies—can help you access Mounjaro affordably ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

The company pointed to “recent market challenges” and “share price decline” as reasons for Lars Fruergaard Jørgensen’s ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...